Details for New Drug Application (NDA): 214443
✉ Email this page to a colleague
NDA 214443 describes ALLOPURINOL, which is a drug marketed by Accord Hlthcare, Aiping Pharm Inc, Chartwell, Endo Operations, Harman Finochem, Hetero Labs Ltd V, Indoco, Ipca Labs Ltd, Lupin Ltd, Mutual Pharm, Mylan, Northstar Hlthcare, Puracap Pharm, Purepac Pharm, Sandoz, Sun Pharm Inds Inc, Sun Pharm Industries, Superpharm, Unichem, Watson Labs, Zydus Pharms, Gland Pharma Ltd, and Hikma, and is included in thirty NDAs. It is available from forty suppliers. Additional details are available on the ALLOPURINOL profile page.
The generic ingredient in ALLOPURINOL is allopurinol sodium. There are twenty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the allopurinol sodium profile page.
The generic ingredient in ALLOPURINOL is allopurinol sodium. There are twenty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the allopurinol sodium profile page.
Summary for 214443
| Tradename: | ALLOPURINOL |
| Applicant: | Harman Finochem |
| Ingredient: | allopurinol |
| Patents: | 0 |
Pharmacology for NDA: 214443
| Mechanism of Action | Xanthine Oxidase Inhibitors |
Medical Subject Heading (MeSH) Categories for 214443
Suppliers and Packaging for NDA: 214443
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ALLOPURINOL | allopurinol | TABLET;ORAL | 214443 | ANDA | NuCare Pharmaceuticals, Inc. | 68071-3672 | 68071-3672-9 | 90 TABLET in 1 BOTTLE (68071-3672-9) |
| ALLOPURINOL | allopurinol | TABLET;ORAL | 214443 | ANDA | Preferred Pharmaceuticals Inc. | 68788-8713 | 68788-8713-1 | 100 TABLET in 1 BOTTLE (68788-8713-1) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 100MG | ||||
| Approval Date: | Mar 7, 2022 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 300MG | ||||
| Approval Date: | Mar 7, 2022 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 200MG | ||||
| Approval Date: | Jun 17, 2024 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
